Reviewnpj antimicrobials and resistance2024
Contribution of the infection ecosystem and biogeography to antibiotic failure in vivo.
Review in npj antimicrobials and resistance, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Postbiotic-Mediated Green Synthesis of Silver Nanoparticles: Revealing Potent Antimicrobial, Anti-Biofilm, Antioxidant, and Anticancer Properties using Paenibacillus xylanexedens.Probiotics and antimicrobial proteins · 2026Article
- Diagnostic Dilemma of Non-resolving Tubal Abscess Caused by Citrobacter amalonaticus Due to Labial Adhesion in a Patient with Pyelonephritis Caused by Escherichia coli, Pyometra and Bacteremia Caused by Bacteroides fragilis.Internal medicine (Tokyo, Japan) · 2026Article
- Preclinical Performance Evaluation of an Oxidized Regenerated Cellulose Hemostat: Antibacterial Activity and Wound Healing Outcomes.Medical devices (Auckland, N.Z.) · 2026Article
- Genome-wide evolutionary selection pressures acting onNAR molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The acquisition of antibiotic resistance in bacteria, though a deeply concerning international issue, is reasonably well-understood at a mechanistic level. Less well-understood is why bacteria that are sensitive in vitro to well-established and widely-used antibiotics sometimes fail to respond to these agents in vivo. This is a particularly common problem in chronic, polymicrobial infection scenarios. Here, we discuss this in vitro-in vivo disconnect from the perspective of the bacterium, focusing in particular on how infection micro/macro-environment, biogeography, and the presence of co-habiting species affect the response to antibiotics. Using selected exemplars, we also consider interventions that might improve treatment outcomes, as well as ecologically 'eubiotic' approaches that have less of an impact on the patient's commensal microflora. In our view, the accrued data strongly suggest that we need a more comprehensive understanding of the in situ microbiology at infection sites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.